Tag
By sales volumes for its GLP-1 drugs, the company’s largest markets in the region are Australia, Japan, South Korea and India With hundreds of millions living with obesity and diabetes…
EUROPEAN shares closed at a new peak on Tuesday, powered by gains in the healthcare sector, after heavyweight Novo Nordisk clinched US approval of its weight-loss pill. The pan-European…
The U.S. Food and Drug Administration approved Novo Nordisk’s weight-loss pill on Monday, giving the Danish drugmaker a leg up in the race to market a potent oral medication for shedding…
The approval gives the drugmaker a first-mover advantage in the race for a potent oral weight-loss medicine [COPENHAGEN/LONDON] Novo Nordisk shares jumped nearly 8 per cent on Tuesday (Dec…
Novo Nordisk’s closely-watched Alzheimer’s trials of an older oral version of its semaglutide drug failed to help slow the progression of the brain-wasting disease, the firm said on…
Novo Nordisk, the Danish drug company that makes Ozempic and Wegovy, is now offering the drugs at lower prices for self-pay patients. On Monday, the company announced it would offer both…
Novo Nordisk has pulled in more than 15 billion euros (S$22.6 billion) of investor orders for its multi-tranche bond sale, more than triple the amount the Danish drugmaker is seeking for…
President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy.…
Pfizer on Friday (Oct 31) filed a lawsuit against Metsera and Novo Nordisk, saying Metsera breached its merger agreement obligations in declaring the Danish drugmaker’s US$8.5 billion bid…
Novo Nordisk, the Danish pharmaceutical giant behind the popular weight-loss drugs Ozempic and Wegovy, just announced plans to cut 11% of its workforce as competitors like Eli Lilly…
Wegovy-maker Novo Nordisk will cut 9,000 jobs, or about 11.5 per cent of its workforce, in a restructuring to save eight billion Danish crowns (S$1.6 billion) annually, it said on…
Wegovy-maker Novo Nordisk will cut 9,000 jobs, or about 11.5 per cent of its workforce, in a restructuring to save eight billion Danish crowns (S$1.6 billion) annually, it said on…
European shares finished marginally higher on Monday (Sep 1), supported by defence stocks, while Novo Nordisk gained after data showed its weight-loss drug Wegovy delivers stronger…
Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service, are currently soaring after the company announced that it will partner with Novo Nordisk to…
Locally headquartered biotech firm KPB Biosciences has failed to set aside a court order for its assets to be frozen, with the Singapore International Commercial Court (SICC) having…
It’s been a week of wins for Eli Lilly’s weight-loss drugs. In the company’s second quarter earnings report on Thursday, it reported that sales of Mounjaro, its type-2 diabetes medication…
Health-related stocks are not having a good day. First, America’s largest health insurance provider, UnitedHealth Group (NYSE: UNH), saw its stock drop more than 4% this morning after the…
This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health, Inc. (NYSE: HIMS), citing concerns…
Novo Nordisk reclaimed its position as Europe’s most valuable public company, overtaking software developer SAP. Shares in the Danish drugmaker climbed as much as 2.3 per cent on…
One day after WeightWatchers said that it would file for bankruptcy, weight loss drug giant Novo Nordisk’s outlook is brightening. Novo Nordisk, the Danish company that produces…
This follows executive orders by President Donald Trump to stop diversity, equity and inclusion initiatives Obesity drugmaker Novo Nordisk said on Wednesday (May 7) it would drop…
EUROPE’S Stoxx 600 closed slightly higher at the start of a holiday-shortened week, as a spike in Novo Nordisk shares boosted the healthcare sector and capped losses on the main stock…
Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted on Wednesday (Nov 6) strong third-quarter earnings despite…
